Abstract:Background: Non–small cell lung cancer (NSCLC) is the most common histologic type of lung cancer, accounting for 70–85% of all lung cancers. It has brought a heavy burden of disease and financial cost to families, society, and the nation of China. Patients have differing preferences for treatment because of their varying physical conditions and socioeconomic backgrounds, which ultimately affects the choice of treatment as well as treatment outcomes. For better and sustained health outcomes, it is vital to understand patients' preferences. We can then provide medical services to match these preferences and needs rather than basing treatment on our clinical viewpoints alone.Objectives: The aim of this study was to elicit patient preferences for treatment using a discrete-choice experiment and to explore the value/importance that patients place on the different attributes of treatment in order to provide a basis for clinical decision making and patient health management.Methods: The study was conducted with NSCLC patients from three typical hospitals in southwestern China. After identifying patient-relevant treatment attributes via literature review and qualitative semi structured interviews, a discrete-choice experiment (DCE) including seven patient-relevant attributes was conducted using a fractional factorial SAS design. The empiric data analyses of patients were performed using mixed logit models.Results: NSCLC patients (N = 202) completed a survey via a face-to-face interview. Among the seven attributes, the following were considered important: progression-free survival, disease control rate, cost, weakness/fatigue, and nausea/vomiting; mode of administration and rash were considered less important. A clear preference for an increase in progression-free survival and disease control rate was demonstrated. Compared with 5 months of progression-free survival, respondents were willing to pay more (19,860 RMB) for 11 months of progression-free survival (coef.: 0.687). Compared with a 60% rate of disease control, respondents were willing to pay more (19,940 RMB) for a 90% rate of disease control (coef.: 0.690).Conclusions: This study demonstrates the value of DCEs in determining patient preferences for the treatment of NSCLC. The results indicate that not only efficacy factors (such as progression-free survival and disease control rate) were considered but also other factors (such as side effects and treatment costs) and trade-offs between attributes were held to be important. These results are in accord with expectations and can provide evidence for more effective and efficient treatment results. Furthermore, the current results can increase benefits if the presented therapies can be designed, assessed, and chosen based on patient-oriented findings.

Study on Disease Treatment Preference and Willingness Payment in Patients with Non-small Cell Lung Cancer

A Study of Patient Preferences for the Treatment of Non–small Cell Lung Cancer in Western China: A Discrete-Choice Experiment

Patient Preferences for Chemotherapy in the Treatment of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study in China

Doctor's Choice Preference for Non-small Cell Lung Cancer Treatment

Preferences and Willingness to Pay for Medication in Patients with Renal Cell Carcinoma in China: A Discrete-Choice Experiment

Differences in Lung Cancer Treatment Preferences among Oncologists, Patients and Family Members: A Semi-Structured Qualitative Study in China.

Physician Preferences for Chemotherapy in the Treatment of Non-Small Cell Lung Cancer in China: Evidence from Multicentre Discrete Choice Experiments

Preferred Lung Cancer Screening Modalities in China: A Discrete Choice Experiment.

Patients' Evaluation and Preference for Adjuvant Chemotherapy in Non-small Cell Lung Caner

Study on the Economic Burden of Lung Cancer Inpatients from One Tertiary Hospital in Shanghai

Association Study of Survival Time and Hospitalization Expenses in Patients of Non-Small Cell Lung Cancer

Ppa_a_224529 1701..1709

Willingness to Pay for Cancer Prevention Versus Treatment in China: Implications for Cost-Effectiveness Threshold.

Eliciting Older Cancer Patients' Preferences for Follow-Up Care to Inform a Primary Healthcare Follow-Up Model in China: A Discrete Choice Experiment.

Patient Preferences and Shared Decision Making for the Traditional Chinese Medicine Treatment of Lung Cancer: A Discrete Choice Experiment Study.

The Cost Of Treating Advanced Non-Small Cell Lung Cancer: Estimates From The Chinese Experience

[Explore the Optimal Resolvent of Medical Needs and Mental Health for Patients with Lung Cancer During Epidemic Novel Coronavirus Pneumonia].

Findings About Patient Preferences for Medical Care Based on a Decision Tree Method Study Design for Influencing Factors

Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment

Treatment Preferences of Residents Assumed to Have Severe Chronic Diseases in China: A Discrete Choice Experiment

National Survey of the Medical Treatment Status for Non-Small Cell Lung Cancer (NSCLC) in China